The anti-obesity efficacy of MNO-863 monotherapy is comparable to that of Liraglutide (GLP-1 analogue), and the combination of MNO-863 and Liraglutide has potential synergistic anti-obesity therapeutic effect. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.